Stoke Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Stoke Therapeutics Inc.
- Former names
- ASOthera Pharmaceuticals, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Bedford
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- STOK
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001623526
- EIN
- 47-1144582
Board of directors
-
Adrian R. Krainer · DirectorSince 2023
-
Alexander Cumbo · DirectorSince 2026
-
Arthur A. Levin · DirectorSince 2023
-
Arthur Tzianabos · Director · Interim Executive ChairSince 2023
-
Clare Kahn · DirectorSince 2026
-
Edward M. Kaye M.D. · Director · CEOSince 2023
-
Garry E. Menzel · DirectorSince 2023
-
Ian F. Smith · Director · Chief Executive OfficerSince 2023
-
Jennifer Burstein · DirectorSince 2023
-
Julie Smith · DirectorSince 2023
-
Seth Loring Harrison · DirectorSince 2023
Chief executives
Edward M. Kaye M.D.
· CEO
Dates unknown
Dates unknown
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
73.0%
-
87.0%
Board connections
7 of this board's directors also sit on 9 other boards.
- via Alexander Cumbo, Clare Kahn and Ian F. Smith
- via Garry E. Menzel
- via Alexander Cumbo
- via Edward M. Kaye M.D.
- via Julie Smith
- via Ian F. Smith
- via Ian F. Smith
- via Arthur Tzianabos
- via Alexander Cumbo
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $11,086,208
- 85 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −3,945 | $30.51 | $120,370 |
| Sep 1, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,600 | $31.06 | $49,691 |
| Aug 18, 2026 | Allan Jonathan Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | −2,716 | $32.01 | $86,932 |
| Aug 18, 2026 | Edward M. Kaye M.D. Director | Open-market sale | −11,930 | $32.01 | $381,846 |
| Aug 18, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −4,525 | $32.01 | $144,833 |
| Aug 18, 2026 | Allan Jonathan Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | −145 | $32.47 | $4,708 |
| Aug 18, 2026 | Edward M. Kaye M.D. Director | Open-market sale | −637 | $32.47 | $20,682 |
| Aug 18, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −242 | $32.47 | $7,857 |
| Aug 14, 2026 | Allan Jonathan Officer (GENERAL COUNSEL & CORP SEC) | Option exercise | +6,000 | — | — |
| Aug 14, 2026 | Edward M. Kaye M.D. Director | Option exercise | +26,250 | — | — |
| Aug 14, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Option exercise | +10,000 | — | — |
| Aug 3, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −5,907 | $28.95 | $171,008 |
| Aug 3, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,269 | $29.45 | $37,377 |
| Jul 1, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −6,728 | $32.62 | $219,434 |
| Jul 1, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −500 | $33.27 | $16,634 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.